多宁生物递表港交所 摩根士丹利与华泰国际担任联席保荐人

Core Viewpoint - Doning Bio has submitted its prospectus to the Hong Kong Stock Exchange, with Morgan Stanley and Huatai International serving as joint sponsors [1] Group 1: Company Overview - Doning Bio operates through a dual-driven model of "bioprocess solutions" and "laboratory products and services," providing high-quality media, bioreactors, single-use products, and filters to global pharmaceutical companies, CROs/CDMOs, and research institutions [1] - The company ranks sixth among all suppliers in China's bioprocess solutions market based on 2024 revenue, and second among local suppliers [1] - Doning Bio leads in several key product categories, including cell culture media, bioreactors, single-use products, and filters among domestic enterprises [1] Group 2: Business Model and Clientele - The company supports pharmaceutical companies, CROs/CDMOs, and research institutions by offering a comprehensive range of reagents, consumables, and equipment covering all major steps of bioprocessing [1] - Doning Bio has served over 3,700 clients, with approximately 80% of major clients opting for long-term cooperation [1] Group 3: Fundraising and Future Plans - The funds raised from the IPO will primarily be used for continuous product development and enhancing the competitive advantage of comprehensive solutions [1] - The company plans to establish R&D centers, production bases, and sales networks overseas to further expand its global market share [1] - There will be an enhancement of production facilities and ongoing investment in R&D to maintain technological leadership [1]